Press releases
- ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
- IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
- ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
- BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
- IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
More ▼
Key statistics
As of last trade Immunoprecise Antibodies Ltd (TQB:DUS) traded at 0.89, 2.30% above its 52-week low of 0.87, set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.90 |
---|---|
High | 0.90 |
Low | 0.89 |
Bid | 0.905 |
Offer | 0.94 |
Previous close | 0.90 |
Average volume | 318.44 |
---|---|
Shares outstanding | 26.32m |
Free float | 22.74m |
P/E (TTM) | -- |
Market cap | 26.44m USD |
EPS (TTM) | -0.4158 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 18:31 BST.
More ▼